Back to Search Start Over

Voltage-gated sodium channel Na v 1.5 promotes tumor progression and enhances chemosensitivity to 5-fluorouracil in colorectal cancer.

Authors :
Sui Q
Peng J
Han K
Lin J
Zhang R
Ou Q
Qin J
Deng Y
Zhou W
Kong L
Tang J
Xiao B
Li Y
Yu L
Fang Y
Ding PR
Pan Z
Source :
Cancer letters [Cancer Lett] 2021 Mar 01; Vol. 500, pp. 119-131. Date of Electronic Publication: 2020 Dec 16.
Publication Year :
2021

Abstract

Na <subscript>v</subscript> 1.5, encoded by SCN5A, has been associated with metastasis in colorectal cancer (CRC). Here, we investigated the mechanism by which Na <subscript>v</subscript> 1.5 regulates tumor progression and whether Na <subscript>v</subscript> 1.5 influences chemosensitivity to 5-fluorouracil (5-FU) in CRCs. CRC cases were evaluated for Na <subscript>v</subscript> 1.5 expression. Elevated Na <subscript>v</subscript> 1.5 expression was associated with poor prognosis in CRCs, whereas stage II/III patients with upregulated SCN5A expression could have better survival after receiving 5-FU-based adjuvant chemotherapy. In CRC cells, SCN5A knockdown reduced the proliferation, migration and invasion. According to RNA sequencing, SCN5A knockdown inhibited both the cell cycle and epithelial-mesenchymal transition. In addition, Na <subscript>v</subscript> 1.5 stabilized the KRas-calmodulin complex to modulate Ras signaling, promoting Ca <superscript>2+</superscript> influx through the Na <superscript>+</superscript> -Ca <superscript>2+</superscript> exchanger and Ca <superscript>2+</superscript> release-activated calcium channel. Meanwhile, SCN5A knockdown increased the 50% inhibitory concentration to 5-FU by upregulating 5-FU-stimulated apoptosis in CRCs. In conclusion, Na <subscript>v</subscript> 1.5 could progress to proliferation and metastasis through Ca <superscript>2+</superscript> /calmodulin-dependent Ras signaling in CRC, and it could also enhance 5-FU-stimulated apoptosis. Clinically, patients with stage II/III CRCs with elevated SCN5A expression demonstrated poor prognosis, yet those patients could benefit more from 5-FU-based chemotherapy than patients with lower SCN5A expression.<br /> (Copyright © 2020 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1872-7980
Volume :
500
Database :
MEDLINE
Journal :
Cancer letters
Publication Type :
Academic Journal
Accession number :
33338532
Full Text :
https://doi.org/10.1016/j.canlet.2020.12.017